Investigating how certain proteins and compounds affect retinal cell regeneration.
Fatty acid binding-proteins and endocannabinoids in the retina; roles in glial reactivity and reprogramming of Muller glia into progenitor cells
This study is looking at how certain proteins and natural compounds in the eye can help special cells called Müller glia turn into new cells that might repair damage, which could lead to new treatments for eye diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10997398 on NIH RePORTER |
What this research studies
This research explores the role of fatty acid binding proteins and endocannabinoids in the retina, particularly focusing on Müller glia, which can transform into progenitor cells that promote neural regeneration. The study aims to understand the mechanisms that stimulate these cells to regenerate in both damaged and undamaged retinas. By using pharmacological and genetic methods, researchers will selectively activate or inhibit these proteins to observe their effects on retinal cell behavior. This could lead to new therapies for degenerative retinal diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from degenerative retinal diseases or conditions that affect retinal cell health.
Not a fit: Patients with stable retinal conditions that do not involve degeneration or damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that enhance retinal regeneration and restore vision in patients with degenerative retinal conditions.
How similar studies have performed: Other research has shown promising results in using similar approaches to stimulate retinal regeneration, indicating potential for success in this area.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Fischer, Andy J — Ohio State University
- Study coordinator: Fischer, Andy J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.